Conference Presentation

4DMT to show 4D-150's two-year wet AMD data ahead of pivotal readouts

PRISM's Phase 2b two-year results, due at a scientific conference in Q3 2026, will be the most mature look yet at 4D-150 before 4FRONT-1 topline data lands in H1 2027.

By AppliedXLJuly 13, 2026Trial NCT05197270

Executive Summary

4D Molecular Therapeutics plans to present two-year follow-up data from its early-phase wet AMD gene therapy trial at a scientific conference, giving investors the longest human dataset yet on the therapy ahead of two Phase 3 readouts.
The company has singled out a specific patient subgroup within this trial as the one most comparable to its Phase 3 population, making this presentation a direct proxy for how the pivotal trials might read out.
The therapy is one of several gene therapy candidates targeting VEGF in wet AMD now in clinical testing, placing this update in a field where the mechanism is established but no single gene therapy has yet won approval in the indication.
The trial's completion date has shifted repeatedly since 2023 even as its enrollment target has been stable since late 2024, a pattern consistent with a maturing trial adding follow-up time rather than a program in distress.

The presentation

4DMT said PRISM's Phase 2b two-year data, covering a broad patient population and a recently diagnosed subgroup, are expected to be presented at a scientific conference in Q3 2026. The company called the recently diagnosed subgroup the population most comparable to the one enrolled in its ongoing Phase 3 4FRONT program. That framing makes this conference presentation a direct proxy for how the pivotal trials, which are testing the same gene therapy delivered intravitreally, might read out. 4DMT

Probability of Success

Endpoint Met65%

Completes61%

Clinical Significance50%

Regulatory62%

The trial and its design

PRISM is registered as NCT05197270, a Phase 1/2, open-label study of 4D-150 against an active aflibercept comparator arm in patients with macular neovascularization secondary to wet AMD who are currently on anti-VEGF therapy. The trial is not registrational, and its primary endpoint is the incidence and severity of treatment-emergent and serious adverse events, a safety measure, with secondary endpoints tracking change in visual acuity, central subfield thickness, and the number and timing of supplemental aflibercept injections over 52 weeks. The trial is Recruiting, with an anticipated enrollment of 215 across ten arms including one active comparator and nine experimental groups. NCT05197270

Timeline history

The trial's primary completion date has moved three times since its 2023 amendment history began: from May 2026 to November 2024, then to November 2025, and most recently to March 2027 in June 2025. Enrollment grew from 65 to 150 and then to 215 across the same period, but has held flat at 215 since November 2024. The completion-date slippage has occurred alongside a stable enrollment target, consistent with a trial adding follow-up duration and expanding sub-studies, including the Shedding and Contralateral Eye sub-studies, rather than a trial struggling to fill. NCT05197270

The stake for 4D-150's franchise

4D-150 is also being tested in the Phase 3 4FRONT-1 trial, which completed randomization of 523 patients in North America in March 2026 with topline data expected in H1 2027, and in 4FRONT-2, a global trial expected to complete enrollment in H2 2026 with topline data due in H2 2027. PRISM's two-year data will be the last major 4D-150 wet AMD dataset investors see before those two pivotal readouts. 4D-150 is also in Phase 3 testing for diabetic macular edema, with two-year SPECTRA data due in H2 2026. 4DMT

The competitive field

Wet AMD gene therapy remains an active but unresolved area: AbbVie's RGX-314 is in Phase 2 testing and Sanofi's SAR402663 is in Phase 1/2, both sharing 4D-150's VEGF target and gene-therapy modality. Standard-of-care anti-VEGF injections such as aflibercept, ranibizumab, and bevacizumab remain the approved comparators, and 4D-150's central value proposition is reducing injection frequency relative to that standard, the same question its secondary endpoints in PRISM are built to answer. No gene therapy has yet reached approval in this indication, so a durability signal in PRISM's two-year data that extends the injection-interval benefit seen at earlier timepoints would be the result most informative for how the Phase 3 program is likely to read. NCT05197270

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.